Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$7.44 USD
-0.11 (-1.46%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.41 -0.03 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Mesoblast Limited [MESO]
Reports for Purchase
Showing records 21 - 40 ( 91 total )
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Regulatory Path for Degenerative Disc Disease
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: $158M in Cash - GvHD, Back Pain and Heart Failure
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: 60-Day ARDS-COVID Data in Patients < 65 Shows Life-Saving (Mortality) Benefit
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Mesoblast Just Raised $110M - Did Anybody Notice?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: DDD Results Look Good - Approval Could Follow Now
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Rexlemestrocel-L Scores A Win in Low Back Pain; Awaiting Regulatory Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Yes DDD Results are Ahead - What?s Priced In?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: COVID ARDS Study is Snafued by Improved SOC
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Counting ARDS Out for Remestemcel-L; Lower PT to $16; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Revascor Shows a 60% Reduction in Death
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Positive MACE and Mortality Results Could Lead to Regulatory Approval in HF; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Novartis Partners with Mesoblast for ARDS If It Works
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
A Vote of Confidence in Remestemcel-L; Higher $20 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
BUY: Remestemcel CRL, but We Could Still see an Approval
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
We See Opportunity in Upcoming Catalysts Despite CRL in GvHD; Lower PT to $19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S